IP Verse

CSPC Megalith Biopharmaceutical Co., Ltd. et al. vs Shanghai Miracogen Inc. et al.

Explore the PTAB proceeding IPR2025-00685 filed by CSPC Megalith Biopharmaceutical Co., Ltd. et al. against Shanghai Miracogen Inc. et al. on Mar 3, 2025. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number
IPR2025-00685
Filing Date
Mar 3, 2025
Petitioner
CSPC Megalith Biopharmaceutical Co., Ltd. et al.
Respondent
Shanghai Miracogen Inc. et al.
Status
Pending
Respondent Application Number
15550995
Respondent Tech Center
1600
Respondent Patent Number
10792370

Proceeding Decision New

Decision documents related to this case provide insights into the outcomes of proceedings. These documents are crucial for understanding the legal determinations and implications for the parties involved.

Document NameFiling DateCategoryFiling Party

Director Discretionary Decision: Refer

Jul 31, 2025PAPERBOARD

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.


Document NameFiling DateCategoryFiling Party

Alert me when new update on this case

Director Discretionary Decision: Refer

Jul 31, 2025PAPERBOARD

Patent Owner's Preliminary Response

Jul 15, 2025PAPERPATENT OWNER

EGFR expression in normal human tissues

Jul 15, 2025EXHIBITPATENT OWNER

CD30 expression in normal human tissues

Jul 15, 2025EXHIBITPATENT OWNER

EP4434549A1

Jul 15, 2025EXHIBITPATENT OWNER

CSPC Announcement

Jul 15, 2025EXHIBITPATENT OWNER

First-in-human study of SYS6010

Jul 15, 2025EXHIBITPATENT OWNER

WO2012100346A1

Jul 15, 2025EXHIBITPATENT OWNER

Preclinical evaluation of HTI-1511

Jul 15, 2025EXHIBITPATENT OWNER

Characterization of ABBV-221

Jul 15, 2025EXHIBITPATENT OWNER

Phase I study of ABBV-321

Jul 15, 2025EXHIBITPATENT OWNER

US20110076232A1

Jul 15, 2025EXHIBITPATENT OWNER

A Study Evaluating Safety and Pharmacokinetics of ABBV-221

Jul 15, 2025EXHIBITPATENT OWNER

Lepu Biopharma Co. Ltd. 2024 Annual Report

Jul 15, 2025EXHIBITPATENT OWNER

Written Opinion of the International Searching Authority for WO2023088382

Jul 15, 2025EXHIBITPATENT OWNER

CSPC Pharmaceutical Group Ltd. Voluntary Announcement, May 19, 2025

Jul 7, 2025EXHIBITPETITIONER

Study of SYS6010 and Platinum-based Chemotherapy in Patients with EGFR-mutated NSCLC, April 15, 2025

Jul 7, 2025EXHIBITPETITIONER

Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors

Jul 7, 2025EXHIBITPETITIONER

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors. Cancer.gov

Jul 7, 2025EXHIBITPETITIONER

Petitioners' Response to Patent Owner's Request for Discretionary Denial of Institution

Jul 7, 2025PAPERPETITIONER

Patent Owner's Request for Discretionary Denial

Jun 6, 2025PAPERPATENT OWNER

International Nonproprietary Names for Pharmaceutical Substances

Jun 6, 2025EXHIBITPATENT OWNER

Han et al. Becotatug Vedotin vs. Chemotherapy

Jun 6, 2025EXHIBITPATENT OWNER

Lepu Biopharma Voluntary Announcement Regarding MRG003

Jun 6, 2025EXHIBITPATENT OWNER

Fast Track _ FDA

Jun 6, 2025EXHIBITPATENT OWNER

Breakthrough Therapy _ FDA

Jun 6, 2025EXHIBITPATENT OWNER

Notice: Notice filing date accorded

Apr 15, 2025PAPERBOARD

Patent Owner's Mandatory Notice

Mar 21, 2025PAPERPATENT OWNER

Patent Owner's Power of Attorney

Mar 21, 2025PAPERPATENT OWNER

U.S. Patent No. 10,792,370 to Hu (“the ’370 patent”)

Mar 3, 2025EXHIBITPETITIONER

File History of U.S. Patent No. 10,792,370 Part 1

Mar 3, 2025EXHIBITPETITIONER

File History of U.S. Patent No. 10,792,370 Part 2

Mar 3, 2025EXHIBITPETITIONER

U.S. Patent Application Publication No. US 2015/071923 (“Wei”)

Mar 3, 2025EXHIBITPETITIONER

International Publication No. WO 2014/152199 (“Leanna”)

Mar 3, 2025EXHIBITPETITIONER

Chinese Patent Application Publication No. CN103772504 (“Liu”)

Mar 3, 2025EXHIBITPETITIONER

Certified English Translation of Chinese Patent App. Pub. No. CN103772504

Mar 3, 2025EXHIBITPETITIONER

International Publication No. WO 2015/000062 (“Tikhomirov”)

Mar 3, 2025EXHIBITPETITIONER

Metrangolo & Engelholm, Cancers (Basel), 16(2):447 (2024)

Mar 3, 2025EXHIBITPETITIONER

Tsurushita, et al., Methods., 36(1):69-83 (2005)

Mar 3, 2025EXHIBITPETITIONER

Jorissen, et al., Exp Cell Res., 284(1):31-53 (2003)

Mar 3, 2025EXHIBITPETITIONER

Olayioye, et al., EMBO J., 19(13):3159-67 (2000)

Mar 3, 2025EXHIBITPETITIONER

Bou-Assaly & Mukherji, AJNR Am J Neuroradiol., 31(4):626-7 (2010)

Mar 3, 2025EXHIBITPETITIONER

McCombs & Owen, AAPS J., 17(2):339-51 (2015)

Mar 3, 2025EXHIBITPETITIONER

Kovtun & Goldmacher, Cancer Lett., 255(2):232-40 (2007)

Mar 3, 2025EXHIBITPETITIONER

Okeley, et al., Clin Cancer Res., 16(3):888-97 (2010)

Mar 3, 2025EXHIBITPETITIONER

Nagaria, et al., Neoplasia,15(8):939-51 (2013)

Mar 3, 2025EXHIBITPETITIONER

Perez, et al., Drug Discovery Today, 19(7): 869-881 (2014)

Mar 3, 2025EXHIBITPETITIONER

Alley, et al., Curr Opin Chem Biol., 14(4):529-37 (2010)

Mar 3, 2025EXHIBITPETITIONER

Younes, et al., Nat Rev Drug Discov., 11(1):19-20 (2012)

Mar 3, 2025EXHIBITPETITIONER

Hwang & Foote, Methods., 36(1):3-10 (2005)

Mar 3, 2025EXHIBITPETITIONER

Herbst & Shin, Cancer., 94(5):1593-611 (2002)

Mar 3, 2025EXHIBITPETITIONER

Martinelli, et al., Clin Exp Immunol., 158(1):1-9 (2009)

Mar 3, 2025EXHIBITPETITIONER

Atalay, et al., Ann Oncol., 14(9):1346-63 (2003)

Mar 3, 2025EXHIBITPETITIONER

Doronina, et al., Nat Biotechnol., 21(7):778–784 (2003)

Mar 3, 2025EXHIBITPETITIONER

Mao, et al., Cancer Res., 64 (3): 781–788 (2004)

Mar 3, 2025EXHIBITPETITIONER

Afar, et al., Mol Cancer Ther., 3(8):921-32 (2004)

Mar 3, 2025EXHIBITPETITIONER

Doronina, et al., Bioconjug Chem., 17(1):114-24 (2006)

Mar 3, 2025EXHIBITPETITIONER

Chinese Patent Application No. 201510085038.8 (“the ’038.8 Provisional”)

Mar 3, 2025EXHIBITPETITIONER

De Goeij, et al., Mol Cancer Ther., 14(5):1130-40 (2015)

Mar 3, 2025EXHIBITPETITIONER

U.S. Patent No. 9,493,568 to Reilly, et al.

Mar 3, 2025EXHIBITPETITIONER

Khan, et al., World J Gastroenterol., 20(11):2979-94 (2014)

Mar 3, 2025EXHIBITPETITIONER

Foltz, et al., Circulation., 127(22):2222-30 (2013)

Mar 3, 2025EXHIBITPETITIONER

Certified English Translation of Chinese Patent App. No. 201510085038.8

Mar 3, 2025EXHIBITPETITIONER

Declaration of Stylianos Bournazos, Ph.D.

Mar 3, 2025EXHIBITPETITIONER

Petition: as filed

Mar 3, 2025PAPERPETITIONER

Notice: Power of Attorney

Mar 3, 2025PAPERPETITIONER